Caldart Federico, Gabriel Charlotte, Vauquelin Blandine, Rivière Pauline, Berger Arthur, Zerbib Frank
CHU de Bordeaux, Centre Médico-chirurgical Magellan, Hôpital Haut-Lévêque, Department of Gastroenterology, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France.
Gastroenterology B Unit, University Hospital Verona, Department of Medicine, University of Verona, Verona, Italy.
Am J Gastroenterol. 2025 May 22;120(8):1770-1778. doi: 10.14309/ajg.0000000000003542.
Esophageal disorders of gut-brain interaction (E-DGBIs) are highly prevalent in patients with unproven gastroesophageal reflux disease (GERD) who do not respond to proton pump inhibitors (PPIs). The aim of this study was to determine the prevalence and characteristics of confirmed refractory GERD and E-DGBIs in consecutive patients with refractory reflux symptoms.
Patients with typical refractory reflux symptoms were prospectively enrolled. Data on age, sex, primary symptoms, pH and pH-impedance monitoring, presence of esophageal motor disorders, and endoscopy results were collected. Patients were classified as unproven and proven GERD, E-DGBI alone, refractory GERD, and overlap between GERD and E-DGBI. Questionnaires were obtained for reflux symptoms, presence of other DGBIs, levels of anxiety and depression, and visceral sensitivity.
A total of 119 patients were included. Among 46 patients with proven GERD, 13 (28%) had isolated refractory GERD and 33 (72%) had an overlap of GERD and E-DGBIs. Among the unproven GERD group, 23 (31.5%) had GERD and 50 (68.5%) had an E-DGBI. Functional dyspepsia (70.6%) and irritable bowel syndrome (33.6%) were highly prevalent. No difference was found in symptom presentation, anxiety, depression, and visceral sensitivity scores. A higher acid exposure time and number of reflux episodes were found in patients with confirmed refractory GERD compared with the overlap E-DGBI-GERD group.
E-DGBIs are highly prevalent in patients with proven GERD and refractory reflux symptoms. Studies with outcome data are needed to determine whether patients with overlapping E-DGBIs and GERD should be identified with pH-impedance monitoring on PPI therapy before an interventional treatment option is considered.
在未经验证的胃食管反流病(GERD)患者中,肠道-脑相互作用的食管疾病(E-DGBIs)非常普遍,这些患者对质子泵抑制剂(PPI)无反应。本研究的目的是确定连续性难治性反流症状患者中确诊的难治性GERD和E-DGBIs的患病率及特征。
前瞻性纳入有典型难治性反流症状的患者。收集年龄、性别、主要症状、pH和pH阻抗监测、食管运动障碍的存在情况以及内镜检查结果等数据。患者被分为未经验证的GERD、已验证的GERD、单独的E-DGBI、难治性GERD以及GERD与E-DGBI重叠组。获取有关反流症状、其他DGBIs的存在情况、焦虑和抑郁水平以及内脏敏感性的问卷。
共纳入119例患者。在46例已验证的GERD患者中,13例(28%)患有孤立性难治性GERD,33例(72%)患有GERD与E-DGBIs重叠。在未经验证的GERD组中,23例(31.5%)患有GERD,50例(68.5%)患有E-DGBI。功能性消化不良(70.6%)和肠易激综合征(33.6%)非常普遍。在症状表现、焦虑、抑郁和内脏敏感性评分方面未发现差异。与GERD与E-DGBI重叠组相比,确诊的难治性GERD患者的酸暴露时间和反流发作次数更高。
E-DGBIs在已验证的GERD和难治性反流症状患者中非常普遍。在考虑介入治疗方案之前,需要有结局数据的研究来确定GERD与E-DGBIs重叠的患者是否应在PPI治疗时通过pH阻抗监测来识别。